Ovid Therapeutics
OVID
42 hedge funds and large institutions have $61.5M invested in Ovid Therapeutics in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 12 increasing their positions, 11 reducing their positions, and 9 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 11
3.13% less ownership
Funds ownership: 32.49% → 29.36% (-3.1%)
7% less funds holding
Funds holding: 45 → 42 (-3)
25% less capital invested
Capital invested by funds: $81.8M → $61.5M (-$20.3M)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$519K |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$392K |
| 3 |
State Street
Boston,
Massachusetts
|
+$186K |
| 4 |
Jennison Associates
New York
|
+$145K |
| 5 |
CI
Cowen Inc
New York
|
+$85K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$3.11M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.41M |
| 3 |
Goldman Sachs
New York
|
-$923K |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$489K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$328K |
OVID Hedge Fund Activity: Q3 2017 in Review
42 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q3 2017, worth a combined $61.5M — down 25% from $81.8M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of OVID and 6 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 12 added.
The largest buyer was Vanguard Group, adding an estimated $519K. The largest seller was Tekla Capital Management, cutting an estimated $3.11M.
- 42 institutional investors held Ovid Therapeutics (OVID) as of Q3 2017, down from 45 in Q2 2017.
- Funds reported $61.5M of Ovid Therapeutics stock for Q3 2017, down 25% quarter-over-quarter.
- 6 funds opened new Ovid Therapeutics positions in Q3 2017 and 9 closed out, a net change of -3 holders.
- The largest Ovid Therapeutics buyer in Q3 2017 was Vanguard Group, an estimated $519K added.
- The largest Ovid Therapeutics seller in Q3 2017 was Tekla Capital Management, an estimated $3.11M sold.
Based on aggregated 13F filings for Q3 2017.